Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2020 Sep 16;21(18):6807.
doi: 10.3390/ijms21186807.

Clinical and Molecular Landscape of ALS Patients with SOD1 Mutations: Novel Pathogenic Variants and Novel Phenotypes. A Single ALS Center Study

Affiliations
Comparative Study

Clinical and Molecular Landscape of ALS Patients with SOD1 Mutations: Novel Pathogenic Variants and Novel Phenotypes. A Single ALS Center Study

Emilien Bernard et al. Int J Mol Sci. .

Abstract

Mutations in the copper zinc superoxide dismutase 1 (SOD1) gene are the second most frequent cause of familial amyotrophic lateral sclerosis (ALS). Nearly 200 mutations of this gene have been described so far. We report all SOD1 pathogenic variants identified in patients followed in the single ALS center of Lyon, France, between 2010 and 2020. Twelve patients from 11 unrelated families are described, including two families with the not yet described H81Y and D126N mutations. Splice site mutations were detected in two families. We discuss implications concerning genetic screening of SOD1 gene in familial and sporadic ALS.

Keywords: SOD1; amyotrophic lateral sclerosis; copper zinc superoxide dismutase 1.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Decline in ALSFRS-R total score among the 12 SOD1 mutated patients.
Figure 2
Figure 2
Pedigrees of the two families harboring the H81Y and D126N mutations. Arrows indicate index patients; black filled icons indicate ALS cases.

Similar articles

Cited by

References

    1. Van Es M.A., Hardiman O., Chio A., Al-Chalabi A., Pasterkamp R.J., Veldink J.H., Van den Berg L.H. Amyotrophic lateral sclerosis. Lancet. 2017;390:2084–2098. doi: 10.1016/S0140-6736(17)31287-4. - DOI - PubMed
    1. Mathis S., Goizet C., Soulages A., Vallat J.M., Masson G.L. Genetics of amyotrophic lateral sclerosis: A review. J. Neurol. Sci. 2019;399:217–226. doi: 10.1016/j.jns.2019.02.030. - DOI - PubMed
    1. Rosen D.R., Siddique T., Patterson D., Figlewicz D.A., Sapp P., Hentati A., Donaldson D., Goto J., O’Regan J.P., Deng H.X., et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;362:59–62. doi: 10.1038/362059a0. - DOI - PubMed
    1. Zou Z.Y., Zhou Z.R., Che C.H., Liu C.Y., He R.L., Huang H.P. Genetic epidemiology of amyotrophic lateral sclerosis: A systematic review and meta-analysis. J. Neurol. Neurosurg. Psychiatry. 2017;88:540–549. doi: 10.1136/jnnp-2016-315018. - DOI - PubMed
    1. Andersen P.M., Nilsson P., Ala-Hurula V., Keränen M.L., Tarvainen I., Haltia T., Nilsson L., Binzer M., Forsgren L., Marklund S.L. Amyotrophic lateral sclerosis associated with homozygosity for an Asp90Ala mutation in CuZn-superoxide dismutase. Nat. Genet. 1995;10:61–66. doi: 10.1038/ng0595-61. - DOI - PubMed

Publication types